BioWorld

Jan. 17, 2006

Genelabs' Prestara Headed For New Phase III Lupus Trial

Forging ahead with its lupus drug, Prestara, Genelabs Technologies Inc. has decided to conduct another Phase III trial, and likely will look for a development partner to help offset costs. (BioWorld Today) Read More

Biotech's Redemption Chance: Make Drugs, Foster Community

Human Bird Flu Data: Less Severe, But More Prevalent

FDA Unveils Guidance To Ease Early Stage Clinical Evaluations

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...